CD274 and cancer: Since PD-L1 showed abnormal expression in a number of cancers and predicted prognosis in patients suffering from these cancers, particularly for those with tumors like LGG, SKCM, THYM, PAAD, OV, TGCT, BRCA, KIRC, LIHC, SARC, and UCEC, it provides guidance for better strategies for the clinical treatment of immune checkpoint inhibitors.